Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
- Address
- Vasvari Pal Utca 2-4, 9024 Győr, Hungary
Cardiovascular Diseases
Research at the site focuses on reducing the risk of recurrent ischemic stroke and high‑risk transient ischemic attacks. Studies aim to test novel antithrombotic agents, evaluate long‑term vascular health, and improve functional recovery after acute events.
- Prevention of recurrent ischemic events
- Evaluation of novel antithrombotic agents
- Assessment of functional outcomes after acute stroke
- Safety monitoring of bleeding risk
- Long‑term vascular health improvement
Gyor‑Moson‑Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz contributes valuable data to cardiovascular research in Europe.
Neoplasms
The hospital conducts a broad oncology program that includes trials for immunotherapy and targeted treatments across hematologic and solid tumors such as chronic lymphocytic leukemia, multiple myeloma, diffuse large B‑cell lymphoma, esophageal carcinoma, metastatic prostate cancer, and non‑small cell lung cancer. The goal is to enhance survival, delay disease progression, and personalize therapy based on molecular profiles.
- Combination immunotherapy trials
- Targeted therapy in solid tumors
- Novel antibody‑drug conjugates
- Personalized treatment based on genetic markers
- Neoadjuvant strategies to enhance surgical outcomes
This research hub in Győr is advancing cancer care through collaborative multi‑center studies.
Respiratory Tract Diseases
Clinical investigations address progressive lung scarring, including idiopathic pulmonary fibrosis and related conditions. Trials evaluate new antifibrotic compounds with the aim of preserving forced vital capacity and improving quality of life for patients with chronic pulmonary fibrosis.
- Antifibrotic drug efficacy
- Long‑term safety in fibrotic lung disease
- Biomarker‑driven patient selection
- Quality‑of‑life assessments
- Pulmonary function preservation
The Győr research facility plays a key role in advancing therapies for respiratory diseases in Hungary and beyond.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 220 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 215 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 32 by active trials.
- 1AstraZeneca AB11active
lock +31 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC28trials
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz
lock Showing 1 of 146 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 220 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 34 | Unknown | 2018-08-24 | 2026-06-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.